MX350195B - Analogos de cistamina para el tratamiento de la enfermedad de parkinson. - Google Patents

Analogos de cistamina para el tratamiento de la enfermedad de parkinson.

Info

Publication number
MX350195B
MX350195B MX2013009608A MX2013009608A MX350195B MX 350195 B MX350195 B MX 350195B MX 2013009608 A MX2013009608 A MX 2013009608A MX 2013009608 A MX2013009608 A MX 2013009608A MX 350195 B MX350195 B MX 350195B
Authority
MX
Mexico
Prior art keywords
parkinson
disease
cystamine
treatment
analogues
Prior art date
Application number
MX2013009608A
Other languages
English (en)
Other versions
MX2013009608A (es
Inventor
Cicchetti Francesca
Rouillard Claude
Calon Frederic
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Publication of MX2013009608A publication Critical patent/MX2013009608A/es
Publication of MX350195B publication Critical patent/MX350195B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de análogos de cistamina para el tratamiento de la enfermedad de Parkinson. La presente invención también se refiere al uso de una composición que comprende análogos de cistamina y cisteína. La presente invención se refiere a un método para modificar el progreso de la enfermedad de Parkinson que comprende administrar una cantidad terapéuticamente efectiva de por lo menos un análogo de cistamina o una sal farmacéuticamente aceptable de un análogo de cistamina a un paciente necesitado del mismo.
MX2013009608A 2011-02-23 2012-02-23 Analogos de cistamina para el tratamiento de la enfermedad de parkinson. MX350195B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161445577P 2011-02-23 2011-02-23
CA2732440A CA2732440C (en) 2011-02-23 2011-02-23 Cystamine analogues for the treatment of parkinson`s disease
PCT/CA2012/050106 WO2012113079A1 (en) 2011-02-23 2012-02-23 Cystamine analogues for the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
MX2013009608A MX2013009608A (es) 2013-09-16
MX350195B true MX350195B (es) 2017-08-30

Family

ID=46717621

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009608A MX350195B (es) 2011-02-23 2012-02-23 Analogos de cistamina para el tratamiento de la enfermedad de parkinson.

Country Status (11)

Country Link
US (1) US20140073694A1 (es)
EP (1) EP2678009B1 (es)
JP (1) JP6000985B2 (es)
KR (1) KR20140115239A (es)
CN (1) CN103442704A (es)
AU (1) AU2012220314B2 (es)
BR (1) BR112013021616A2 (es)
CA (1) CA2732440C (es)
MX (1) MX350195B (es)
RU (1) RU2630583C2 (es)
WO (1) WO2012113079A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI659209B (zh) * 2013-06-17 2019-05-11 地平線罕見醫學製藥有限責任公司 分析半胱胺組合物的方法
TW201618760A (zh) * 2014-11-05 2016-06-01 雷普特製藥有限公司 使用半胱胺組合物治療亨廷頓氏病之方法
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
RU2766579C2 (ru) * 2015-07-02 2022-03-15 ХОРАЙЗОН ОРФАН ЭлЭлСи Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение
US10764961B2 (en) 2016-03-30 2020-09-01 Guangdong Oppo Mobile Telecommunications Corp., Ltd. Relay transmission method and device
EP3946298A4 (en) * 2019-03-26 2023-01-25 The Regents of the University of California SUBSTITUTED AMINO-THIOL AND AMINODISULFIDE COMPOUNDS AND THEIR USES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514942A1 (en) * 2003-02-02 2004-08-19 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Methods and compositions for the treatment of parkinson's disease and other a-synucleinopathies
RU2255775C1 (ru) * 2003-12-25 2005-07-10 Государственное учреждение научно-исследовательский институт неврологии Российской академии медицинских наук Способ лечения болезни паркинсона
EA201600089A1 (ru) * 2006-01-27 2017-01-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Покрытые энтеросолюбильной оболочкой цистеамин и цистамин и их производные
WO2008143876A2 (en) * 2007-05-14 2008-11-27 The Trustees Of Columia University In The City Of New York Agents and assays for modulating neurodegeneration
CA2727022A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries Ltd. Rasagiline for parkinson's disease modification

Also Published As

Publication number Publication date
JP2014508758A (ja) 2014-04-10
WO2012113079A1 (en) 2012-08-30
KR20140115239A (ko) 2014-09-30
EP2678009A1 (en) 2014-01-01
AU2012220314A1 (en) 2013-08-22
RU2630583C2 (ru) 2017-09-11
US20140073694A1 (en) 2014-03-13
EP2678009B1 (en) 2017-11-01
RU2013137645A (ru) 2015-02-20
BR112013021616A2 (pt) 2020-09-29
EP2678009A4 (en) 2014-08-06
CN103442704A (zh) 2013-12-11
JP6000985B2 (ja) 2016-10-05
CA2732440C (en) 2017-10-31
CA2732440A1 (en) 2012-08-23
MX2013009608A (es) 2013-09-16
AU2012220314B2 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington&#39;s disease
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
NZ600000A (en) Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MX2016009427A (es) Formulaciones de pridopidina de liberacion modificada.
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
MX2015006120A (es) Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos.
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
WO2013085849A3 (en) Sulfate esters of noribogaine
MX2013008715A (es) Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco.
AU2018253538A1 (en) Levodopa formulations for rapid relief of parkinson&#39;s disease
EA201290856A1 (ru) Стабилизированная фармацевтическая композиция
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2014002817A (es) Suspension oral.
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
TW201129361A (en) Methods for treating pain

Legal Events

Date Code Title Description
FG Grant or registration